Vaxart, Inc. Enters into A Lease Agreement with Britannia Pointe Grand Limited Partnership
September 21, 2021 at 04:19 pm EDT
Share
On September 17, 2021, Vaxart, Inc. entered into a lease agreement with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership, pursuant to which the Company will have approximately 24,606 square feet of rentable space located at 170 Harbor Way, South San Francisco, California 94080. The Company is currently occupying the Harbor Way Premises pursuant to that certain sublease, dated November 13, 2020, between the Company and Vera Therapeutics, Inc., a Delaware corporation. Pursuant to the Britannia Lease Agreement, the Company will rent the Harbor Way Premises for a term of forty-two months, commencing on October 1, 2025, and expiring on March 31, 2029. The Company will pay monthly rent of $177,327.23, subject to yearly increases as specified in the Britannia Lease Agreement. On September 17, 2021, the Company entered into the Second Amendment to Lease Agreement with Healthpeak Properties, Inc., a Maryland corporation. The Second Amendment amends the Lease Agreement, dated April 17, 2015, as amended by that certain First Amendment to Lease Agreement, dated September 17, 2019.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
VAXART, INC. 
